Health insurer Cigna said its shareholders Friday morning approved the company’s proposed $67 billion purchase of pharmacy benefits manager Express Scripts.
During a special meeting Friday, about 90% of shareholders approved the merger agreement despite recent pushback from activist shareholder Carl Icahn and Sen. Chuck Grassley from Iowa, the top Republican on the Senate Judiciary Committee.
“Our combined company will enhance Cigna’s differentiated service-based model, fueled by actionable insights and analytics, to drive innovation and meaningful growth in a highly dynamic market environment,” Cigna CEO David Cordani said in a statement. “As a result, we will build more effective partnerships, further improve health outcomes and deliver a superior customer experience.”
The US Department of Justice is performing an antitrust review of the proposed merger, which is expected to be completed later this year. Cigna said it expects the deal, subject to customary closing conditions and regulatory approvals, to close by year-end 2018.
Full Content: Forbes
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
Lawmaker Probes FTC and EU’s Role in Amazon’s Failed iRobot Acquisition
May 2, 2024 by
CPI
FTC to Approve Exxon’s $64 Billion Deal with Pioneer Resources, Excludes
May 1, 2024 by
CPI
UK Competition Watchdog Raises Alarm Over Nvidia’s ARM Takeover
May 1, 2024 by
CPI
Sen. Klobuchar Urges Regulators to Probe Collusion in Healthcare Pricing
May 1, 2024 by
CPI
Multiple States Join Tennessee’s Antitrust Lawsuit Against NCAA Over NIL Rules
May 1, 2024 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Economics of Criminal Antitrust
Apr 19, 2024 by
CPI
Navigating Economic Expert Work in Criminal Antitrust Litigation
Apr 19, 2024 by
CPI
The Increased Importance of Economics in Cartel Cases
Apr 19, 2024 by
CPI
A Law and Economics Analysis of the Antitrust Treatment of Physician Collective Price Agreements
Apr 19, 2024 by
CPI
Information Exchange In Criminal Antitrust Cases: How Economic Testimony Can Tip The Scales
Apr 19, 2024 by
CPI